Senseera Health
A Single Blood Test for Broad Monitoring of Human Health.
Company Overview
Snapshot
Founded in August 2020 by Ronen Sadeh, Nir Friedman, Jenia Gutin, and Israa Sharkia, Senseera Health operates with 11–50 employees. The company has raised $7.1 million across three funding rounds from three investors. In January 2025, Senseera Health secured a Seed round from Lightspeed Venture Partners and I-NEXT Capital.
Business overview
Senseera Health is a Health Tech & Life Sciences company developing a new generation of liquid biopsy blood tests. The company utilizes molecular biology, next-generation sequencing, and advanced computational analysis to extract epigenetic information from circulating chromatin fragments in the blood. This technology, cfChIP-seq, aims to provide unparalleled information about disease processes in internal organs and the immune system. Senseera Health's initial product line focuses on accurate, sensitive, and affordable blood tests for early cancer detection and monitoring, serving the diagnostics and laboratories markets.
Strategic signal
In January 2025, Senseera Health successfully closed a $7.1 million Seed funding round. This capital infusion is a strong validation of the company's innovative liquid biopsy platform and its potential to transform disease diagnosis and treatment. The investment signals confidence in Senseera Health's ability to advance its technology and expand its impact in the medical technology sector, particularly in early cancer detection and monitoring.
Log in to access full profile ›Company Intelligence Q&A
- What was Senseera Health's most recent funding activity?
- In January 2025, Senseera Health raised a Seed funding round of $7.1 million from Lightspeed Venture Partners and I-NEXT Capital. This funding is intended to advance its liquid biopsy platform.
- When was Senseera Health founded and by whom?
- Senseera Health was founded in August 2020 by Ronen Sadeh, Nir Friedman, Jenia Gutin, and Israa Sharkia.
- What is Senseera Health's core technology?
- Senseera Health's core technology is cfChIP-seq, which uses molecular biology, next-generation sequencing, and advanced computational analysis to extract epigenetic information from chromatin fragments circulating in the blood for disease detection.
- Has Senseera Health received any grants?
- In October 2021, Senseera Health secured a grant from the Israel Innovation Authority to support its medical technology projects.
- What is Senseera Health's primary focus for its initial products?
- Senseera Health's first line of products is focused on developing an accurate, sensitive, and affordable blood test for the early detection and monitoring of cancer.